Diagnosis and Therapy of Age-Related Macular Degeneration

Literature Review

Penulis

DOI:

https://doi.org/10.55175/rxrdxc67

Kata Kunci:

Age-related macular degeneration, antioxidant vitamins, AREDS2, lutein, nutritional supplementation, zeaxanthin

Abstrak

Age-related macular degeneration (AMD) is one of the leading causes of central vision loss in older adults and is becoming an increasingly important health problem in aging populations. This disease involves complex interactions among oxidative stress, chronic inflammation, retinal pigment epithelium dysfunction, changes in Bruch’s membrane, complement system dysregulation, and genetic factors. Diagnostic advances in retinal imaging, particularly optical coherence tomography (OCT), and a better understanding of morphological and molecular biomarkers have expanded clinicians’ ability to recognize disease course, assess progression risk, and evaluate treatment response. From a therapeutic perspective, AMD management includes AREDS2-based nutritional supplementation in selected cases, anti-vascular endothelial growth factor (anti-VEGF) therapy for the neovascular form, and the development of new approaches such as gene therapy and long-term drug delivery systems. This review briefly discusses the diagnostic and therapeutic aspects of AMD to support evidence-based understanding and clinical practice. Early recognition and appropriate management are important for preserving vision and guiding patient care.

Unduhan

Data unduhan tidak tersedia.

Referensi

1. Trincao-Marques J, Ayton LN, Hickey DG, Marques-Neves C, Guymer RH, Edwards TL, et al. Gene and cell therapy for age-related macular degeneration: a review. Surv Ophthalmol. 2024;69(5):665–76. doi: 10.1016/j.survophthal.2024.05.002.

2. Paudel N, Brady L, Stratieva P, Galvin O, Lui B, Van den Brande I, et al. Economic burden of late-stage age-related macular degeneration in Bulgaria, Germany, and the US. JAMA Ophthalmol. 2024;142(12):1123–30. doi: 10.1001/jamaophthalmol.2024.4401.

3. Maruyama-Inoue M, Kitajima Y, Yanagi Y, Inoue T, Kadonosono K. Intravitreal anti-vascular endothelial growth factor monotherapy in age- related macular degeneration with submacular hemorrhage. Sci Rep. 2023;13(1):5688. doi: 10.1038/s41598-023-32874-0.

4. Zhang J, Liu Z, Hu S, Qi J. Meta-analysis of the pharmacogenetics of ARMS2 A69S polymorphism and the response to advanced age-related macular degeneration. Ophthalmic Res. 2021;64(2):192–204. doi: 10.1159/000508738.

5. Lee Y, Ahn EJ, Hussain A. Saponin-mediated rejuvenation of Bruch’s membrane: a new strategy for intervention in dry age-related macular degeneration (AMD). In: Davey PG, editor. Recent advances and new perspectives in managing macular degeneration [Internet]. London: IntechOpen; 2022 [cited 2026 Oct 10]. Available from: https://www.intechopen.com/chapters/75816.

6. Taylor DJ, Jones L, Binns AM, Crabb DP. 'You've got dry macular degeneration, end of story': a qualitative study into the experience of living with non-neovascular age-related macular degeneration. Eye (Lond). 2019;34(3):461–73. doi: 10.1038/s41433-019-0559-z.

7. Christen WG, Cook NR, Manson JE, Buring JE, Chasman DI, Lee IM, et al. Effect of vitamin D and ω-3 fatty acid supplementation on risk of age-related macular degeneration: an ancillary study of the VITAL randomized clinical trial. JAMA Ophthalmol. 2020;138(12):1280–9. doi:10.1001/jamaophthalmol.2020.4409.

8. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16. doi: 10.1016/S2214-109X(13)70145-1.

9. Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14(9):e29583. doi: 10.7759/cureus.29583.

10. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–34. doi: 10.1016/S2214-109X(17)30393-5.

11. Lukacs R, Schneider M, Nagy ZZ, Sandor GL, Kaan K, Asztalos A, et al. Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. BMC Ophthalmol. 2023;23(1):110. doi: 10.1186/s12886-023-02843-2.

12. Gelfman CM, Grishanin R, Bender KO, Nguyen A, Greengard J, Sharma P, et al. Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema. J Ocul Pharmacol Ther. 2021;37(3):181–90. doi: 10.1089/jop.2021.0001.

13. Heesterbeek TJ, Lores-Motta L, Hoyng CB, Lechanteur YTE, Den Hollander AI. Risk factors for progression of age-related macular degeneration. Ophthalmic Physiol Opt. 2020;40(2):140–70. doi: 10.1111/opo.12675.

14. Chen Y, Ye X, Escames G, Lei W, Zhang X, Li M, et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett. 2023;28(1):51. doi: 10.1186/s11658-023-00462-9.

15. Wong JHC, Ma JYW, Jobling AI, Brandli A, Greferath U, Fletcher EL, et al. Exploring the pathogenesis of age-related macular degeneration: a review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. Front Neurosci. 2022;16:1009599. doi: 10.3389/fnins.2022.1009599.

16. Corazza P, Maddison J, Bonetti P, Guo L, Luong V, Garfinkel A, et al. Predicting wet age-related macular degeneration (AMD) using DARC (detecting apoptosing retinal cells) AI (artificial intelligence) technology. Expert Rev Mol Diagn. 2021;21(1):109–18. doi:10.1080/14737159.2020.1865806.

17. Piri N, Kaplan HJ. Role of complement in the onset of age-related macular degeneration. Biomolecules. 2023;13(5):832. doi: 10.3390/biom13050832.

18. Becerra SP, Dass CR, Yabe T, Crawford SE. Pigment epithelium-derived factor: chemistry, structure, biology, and applications. J Biomed Biotechnol. 2012;2012:830975. doi: 10.1155/2012/830975.

19. Williams MA, Craig D, Passmore P, Silvestri G. Retinal drusen: harbingers of age, safe havens for trouble. Age Ageing. 2009;38(6):648–54. doi: 10.1093/ageing/afp136.

20. Mandic K, Vukojevic N, Jukic T, Katusic D, Juri Mandic J. Changes of drusen number and central retinal thickness in age-related macular degeneration patients over two years. Acta Clin Croat. 2016;55(3):354–9. doi: 10.20471/acc.2016.55.03.02.

21. Yalcinsoy KO, Erol YO, Hondur G, Ozdal PC. Quantitative evaluation of retinal and choroidal microcirculation in inactive ocular sarcoidosis. Indian J Ophthalmol. 2023;71(10):3367–74. doi: 10.4103/IJO.IJO_3262_22.

22. Chew EY, Clemons TE, Agron E, Domalpally A, Keenan TDL, Vitale S, et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28. JAMA Ophthalmol. 2022;140(7):692–8. doi: 10.1001/jamaophthalmol.2022.1640.

23. Ren X, Leveillard T. Modulating antioxidant systems as a therapeutic approach to retinal degeneration. Redox Biol. 2022;57:102510. doi: 10.1016/j.redox.2022.102510.

24. Thananjeyan AL, Arnold J, Lee M, Au C, Pye V, Madigan MC, et al. Basal linear deposit: normal physiological ageing or a defining lesion of age-related macular degeneration? J Clin Med. 2024;13(16):4611. doi: 10.3390/jcm13164611.

25. Sura AA, Chen L, Messinger JD, Swain TA, McGwin Jr G, Freund KB, et al. Measuring the contributions of basal laminar deposit and Bruch's membrane in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2020;61(13):19. doi: 10.1167/iovs.61.13.19.

26. Vinkovic M, Kopic A, Benasic T. Anti-VEGF treatment and optical coherence tomography biomarkers in wet age-related macular degeneration. In: Davey PG, editor. Recent advances and new perspectives in managing macular degeneration [Internet]. London: IntechOpen; 2022 [cited 2026 Oct 10]. Available from: https://www.intechopen.com/chapters/76806.

27. Kardol-Hoefnagel T, Michielsen LA, Ehlers AM, Van Zuilen AD, Luijk B, Otten HG. Complement component C3 and C5b-9 deposition on hypoxia reperfused endothelial cells by non-HLA antibodies against RhoGDI2: a player involved in graft failure? HLA. 2023;101(2):103–14. doi: 10.1111/tan.14858.

28. Chauvet S, Hauer JJ, Petitprez F, Rabant M, Martins PV, Baudouin V, et al. Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. Kidney Int. 2022;102(4):904–16. doi: 10.1016/j.kint.2022.05.027.

29. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28(1):1–18. doi: 10.1016/j. preteyeres.2008.10.001.

30. de Sa Quirino-Makarczyk L, de Fatima Sainz Ugarte M. OCT biomarkers for AMD. In: Davey PG, editor. Recent advances and new perspectives in managing macular degeneration [Internet]. London: IntechOpen; 2022 [cited 2026 Oct 10]. Available from: https://www.intechopen.com/chapters/76690.

31. Sin M. Brolucizumab - a new player in the field of anti-VEGF therapy of neovascular age-related macular degeneration. a review. Cesk Slov Oftalmol. 2022;78(1):3–8. doi: 10.31348/2021/19.

32. Hanson RLW, Airody A, Sivaprasad S, Gale RP. Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review. Eye (Lond). 2023;37(12):2438–53. doi: 10.1038/s41433-022-02360-4.

33. He W, Han X, Ong JS, Wu Y, Hewitt AW, Mackey DA, et al. Genome-wide meta-analysis identifies risk loci and improves disease prediction of age-related macular degeneration. Ophthalmology. 2024;131(1):16–29. doi: 10.1016/j.ophtha.2023.08.023.

34. Black JRM, Clark SJ. Age-related macular degeneration: genome-wide association studies to translation. Genet Med. 2016;18(4):283–9. doi: 10.1038/gim.2015.70.

35. Sharma NK, Gupta A, Prabhakar S, Singh R, Sharma SK, Chen W, et al. Association between CFH Y402H polymorphism and age related macular degeneration in North Indian cohort. PLoS One. 2013;8(7):e70193. doi: 10.1371/journal.pone.0070193.

36. Wu M, Xiong H, Xu Y, Xiong X, Zou H, Zheng M, et al. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. Br J Ophthalmol. 2017;101(7):976–84. doi: 10.1136/bjophthalmol-2016-309418.

37. Tenbrock L, Wolf J, Boneva S, Schlecht A, Agostini H, Wieghofer P, et al. Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives. Cell Tissue Res. 2022;387(3):361–75. doi: 10.1007/s00441-021-03514-8.

38. Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963–76. doi: 10.1016/j.ophtha.2019.12.031.

39. Karasavvidou EM, Tranos P, Panos GD. Brolucizumab for the treatment of degenerative macular conditions: a review of clinical studies. Drug Des Devel Ther. 2022;16:2659–80. doi: 10.2147/DDDT.S378450.

40. Apte RS. Age-related macular degeneration. N Engl J Med. 2021;385(6):539–47. doi: 10.1056/NEJMcp2102061.

41. Vega LL, Herrero IA, Gutierrez AM, Medina JH, Cruz NM, Lara JFA, et al. Evidence-based practice and trends in visual rehabilitation for patients with age-related macular degeneration. In: Davey PG, editor. Recent advances and new perspectives in managing macular degeneration [Internet]. London: IntechOpen; 2022 [cited 2026 Oct 10]. Available from: https://www.intechopen.com/chapters/75711.

42. Shirian JD, Shukla P, Singh RP. Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. Eye (Lond). 2025;39(1):40–4. doi: 10.1038/s41433-024-03373-x.

43. Castro BFM, Steel JC, Layton CJ. AAV-based strategies for treatment of retinal and choroidal vascular diseases: advances in age-related macular degeneration and diabetic retinopathy therapies. BioDrugs. 2024;38(1):73–93. doi: 10.1007/s40259-023-00629-y.

44. Singh M, Negi R, Alka, Vinayagam R, Kang SG, Shukla P. Age-related macular degeneration (AMD): pathophysiology, drug targeting approaches, and recent developments in nanotherapeutics. Medicina (Kaunas). 2024;60(10):1647. doi: 10.3390/medicina60101647.

Diterbitkan

2026-11-19

Cara Mengutip

Diagnosis and Therapy of Age-Related Macular Degeneration: Literature Review. (2026). Cermin Dunia Kedokteran, 53(11), 794-803. https://doi.org/10.55175/rxrdxc67